Medexus Pharmaceutical Inc. (OTCQX: PDDPF) (TSX.V: MDP) is a leading specialty pharmaceutical company with a strong North American commercial platform. The company’s vision is to provide the best health care products to health care professionals and patients, through its core values of quality, innovation, customer service and teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy. The company’s leading products are: Rasuvo(TM) and Metoject(R), a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY(R), an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall(R), an innovative prescription allergy medication with a unique mode of action. For more information, visit the company’s website at www.medexus.com
About The LD 500
The LD 500 is the most ambitious project in LD Micro’s 14-year history of leading the micro-cap space as an independent resource. Investors will enjoy updates from hundreds of companies that represent a wide variety of industries. Featuring some of the most prominent companies in the micro-cap world, the LD 500 also incorporates interviews and keynotes with small-cap royalty.
To view InvestorBrandNetwork’s virtual coverage, which includes one-click access to market research tools on the presenting companies, visit: http://ibn.fm/TheLD500
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
